Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

The emerging role of exosomes as novel therapeutics: Biology, technologies, clinical applications, and the next

Song Y., Kim Y., Ha S., Sheller-Miller S., Yoo J., Choi C.

Clinical Trial, published in Am J Reprod Immunol (2021) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Am J Reprod Immunol (2021)
Reported sample size
—
Source database
Europe PMC
PMID
32846024
PMCID
PMC7900947
DOI
10.1111/aji.13329
Citations
60

Abstract (original English)

The extracellular vesicles (EVs) research area has grown rapidly because of their pivotal roles in intercellular communications and maintaining homeostasis of individual organism. As a subtype of EVs, exosomes are made via unique biogenesis pathway and exhibit disparate functional and phenotypic characteristics. Functionally, exosomes transfer biological messages from donor cell to recipient cell, which makes exosomes as a novel therapeutic platform delivering therapeutic materials to the target tissue/cell. Currently, both academia and industry try to develop exosome platform-based therapeutics for disease management, some of which are already in clinical trials. In this review, we will discuss focusing on therapeutic values of exosomes, recent advances in therapeutic exosome platform development, and late development of exosome therapeutics in diverse therapeutic areas.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsHumansBiological TherapyDrug Delivery SystemsCell CommunicationExosomesExtracellular Vesicles

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.